Placebo to Boceprevir — Competitive Intelligence Brief

Placebo to Boceprevir (Placebo to Boceprevir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor. Area: Infectious Disease.

phase 3 Protease inhibitor NS3/4A protease Infectious Disease Small molecule

Target snapshot

Placebo to Boceprevir (Placebo to Boceprevir) — Merck Sharp & Dohme LLC. Boceprevir is a protease inhibitor that works by blocking the replication of the hepatitis C virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to Boceprevir TARGET	Placebo to Boceprevir	Merck Sharp & Dohme LLC	phase 3	Protease inhibitor	NS3/4A protease
Post-transplant Grazoprevir and Elbasvir	Post-transplant Grazoprevir and Elbasvir	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
OBV/PTV/r and DSV	OBV/PTV/r and DSV	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B polymerase
glecaprevir/pibrentasvir tablets	glecaprevir/pibrentasvir tablets	Raymond T. Chung, MD	marketed	Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor)	HCV NS3/4A protease and NS5A protein
Ombitasvir-Paritaprevir-Ritonavir	Ombitasvir-Paritaprevir-Ritonavir	University of Modena and Reggio Emilia	marketed	HCV protease inhibitor and NS5A inhibitor combination	HCV NS3/4A protease, HCV NS5A protein
paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin	American Research Corporation	marketed	HCV protease inhibitor / NS5A inhibitor / polymerase inhibitor combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor class)

1. Pfizer · 4 drugs in this class
2. French National Agency for Research on AIDS and Viral Hepatitis · 4 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Christopher J. McLeod · 1 drug in this class
5. Hoffmann-La Roche · 1 drug in this class
6. Janssen R&D Ireland · 1 drug in this class
7. Janssen-Cilag International NV · 1 drug in this class
8. Johns Hopkins University · 1 drug in this class
9. Medical Research Council · 1 drug in this class
10. Pfizer Inc. · 1 drug in this class